PixarBio Corp. To Establish Medical Research Center-Corporate Headquarters In Medford, Massachusetts
12/13/2013
Located in close proximity to its innovation roots at Harvard and MIT, PixarBio Corp. said it will have capacity to quickly expand beyond biomaterials needed for Parkinson’s disease to include biomaterials for Epilepsy.
“We are building a home for our world renowned and award winning team of researchers to drive innovation and accelerate the development of new treatment options for Parkinson’s disease. We’re confident that our optimized R&D model will generate key intellectual property permitting PixarBio to lead the development of next generation biomaterials for the treatment of Parkinson’s disease as well as a range of chronic neurological conditions,” says CTO Randy Holmes-Farley, PhD.
Frank Reynolds, PixarBio’s CEO adds, “We’ll move to Medford, MA in early 2014 and get to work on achieving our objective of rapidly bringing a new Parkinson’s treatment to market. Along the way we’ll explore M&A in the biomaterials space while focusing on expanding our platform.”
Project Announcements
Lattice Materials Expands Bozeman, Montana, Manufacturing Operations
01/14/2026
xAI Plans Southaven, Mississippi, Data Center Operations
01/14/2026
Canada-Based GreenPower Plans Santa Teresa, New Mexico, Headquarters Operations
01/14/2026
Integrated Rail and Resources Plans Uintah County, Utah, Operations
01/13/2026
MCM Engineering II Expands Enoch, Utah, Operations
01/12/2026
Lithium Battery Company Plans Tampa, Florida, Battery Pack Production Operations
01/10/2026
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Data Centers in 2025: When Power Became the Gatekeeper
Q4 2025
-
Speed Built In—The Real Differentiator for 2026 Site Selection Projects
Q1 2026
-
Preparing for the Next USMCA Shake-Up
Q4 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
Strategic Industries at the Crossroads: Defense, Aerospace, and Maritime Enter 2026
Q1 2026